Benjamin Golway

Benjamin Golway supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that sustain the agency’s regulatory science infrastructure. He manages a diverse portfolio of contracts focused on scientific testing services, analytical instrumentation, and specialized consulting to advance the FDA’s mandate in ensuring the safety and efficacy of medical products. His acquisitions directly enable laboratory operations, toxicological research, and clinical trial support, aligning with the agency’s strategic priorities in regulatory science and public health protection. Golway maintains consistent working relationships with key contractors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for niche, high-expertise vendors capable of delivering specialized scientific and technical services. His procurement patterns emphasize long-term, performance-based partnerships with firms possessing deep domain knowledge in clinical research, toxicology, and analytical validation—often requiring stringent compliance with FDA regulatory standards and Good Laboratory Practices. His contracting approach prioritizes open competition, with 75% of awards issued without set-aside designations, while maintaining a meaningful 25% commitment to total small business set-asides under FAR 19.5. This balance reflects a strategic focus on accessing specialized capabilities while actively supporting small business participation across the scientific and technical services sector. Golway’s procurement focus centers on NAICS codes 541380 (Testing Laboratories and Services), 541611 (Management Consulting), and 541990 (Other Professional Services), with additional emphasis on 333316 (Medical and Diagnostic Equipment) and 541519 (Other Computer-Related Services). He regularly acquires high-precision analytical instruments, laboratory support services, clinical trial management, and data analytics solutions critical to FDA’s regulatory decision-making, demonstrating expertise in procuring technically complex, compliance-sensitive goods and services essential to public health oversight.